{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T01:40:47Z","timestamp":1747186847863,"version":"3.40.5"},"reference-count":12,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This article discusses the impact of Hepatitis D virus (HDV) infection as a major cause of liver\u2010related morbidity and mortality in people with Hepatitis B virus (HBV) infection. The article reviews the current knowledge and unanswered questions about the epidemiology, pathogenesis, and natural history of HDV infection. Although effective treatments for HDV infection have been elusive, interferon alfa is recommended for at least 48 weeks. However, response rates with standard\u2010of\u2010care peginterferon alfa are suboptimal, leading to few patients with a sustained virologic response. The article proposes novel approaches to treating HDV and HBV, including targeting reduction or loss of hepatitis B surface antigen (HBsAg) reduction, and discusses potential strategies for achieving HBsAg loss in patients with chronic HBV infection. Finally, the article discusses the landmark decision of accepting viral and biochemical surrogates by regulatory authorities, opening the door for the clinical development of drugs for patients with HDV infection.<\/jats:p>","DOI":"10.1111\/jvh.13825","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T14:13:35Z","timestamp":1677680015000},"page":"40-43","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hepatitis D virus infection: Progress on the path toward disease control and cure"],"prefix":"10.1111","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-6352","authenticated-orcid":false,"given":"Mark S.","family":"Sulkowski","sequence":"first","affiliation":[{"name":"Johns Hopkins University School of Medicine  Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,4,7]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_7_2_1","DOI":"10.1136\/gut.18.12.997"},{"doi-asserted-by":"publisher","key":"e_1_2_7_3_1","DOI":"10.1002\/cld.1033"},{"doi-asserted-by":"publisher","key":"e_1_2_7_4_1","DOI":"10.1073\/pnas.77.10.6124"},{"doi-asserted-by":"publisher","key":"e_1_2_7_5_1","DOI":"10.1053\/j.gastro.2004.03.017"},{"doi-asserted-by":"publisher","key":"e_1_2_7_6_1","DOI":"10.1056\/NEJM199401133300202"},{"unstructured":"Office of Communications Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration.Chronic Hepatitis D Virus Infection: Developing Drugs for Treatment Guidance for Industry (fda.gov) October 2019.","key":"e_1_2_7_7_1"},{"doi-asserted-by":"publisher","key":"e_1_2_7_8_1","DOI":"10.1016\/j.jhep.2018.09.014"},{"doi-asserted-by":"publisher","key":"e_1_2_7_9_1","DOI":"10.1016\/S2468-1253(17)30288-1"},{"doi-asserted-by":"publisher","key":"e_1_2_7_10_1","DOI":"10.1056\/NEJMoa2210027"},{"doi-asserted-by":"publisher","key":"e_1_2_7_11_1","DOI":"10.1016\/j.jhep.2022.06.010"},{"unstructured":"Hepcludex 2mg powder for solution for injection Emceuropaedu. Sep 07 2022https:\/\/www.medicines.org.uk\/emc\/product\/13482","key":"e_1_2_7_12_1"},{"doi-asserted-by":"publisher","key":"e_1_2_7_13_1","DOI":"10.1136\/gutjnl-2020-323888"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13825","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13825","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T04:05:37Z","timestamp":1692331537000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.13825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":12,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1111\/jvh.13825"],"URL":"https:\/\/doi.org\/10.1111\/jvh.13825","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"type":"print","value":"1352-0504"},{"type":"electronic","value":"1365-2893"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"2023-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}